Biogen in the NEWS
Today, March 30, 2026, Biogen Inc (BIIB) announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. FDA for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data . . .
This content is for paid subscribers.
Today’s Highlights
March 30, 2026
 for Spinal Muscular Atrophy){kind=link}